Slide 1WE ARE EARLY PHASESlide 2TRIAL EXPERTISESlide 3THERAPEUTIC EXPERTISE We are EARLY Phase We do one thing only, and we do it reliably in all shapes and colours – even yours. FIND OUT WHO WE ARE Trial Expertise We deliver reliable research on everything first-in-human. And we do it in every relevant field and in our own clinical facilities. LEARN ABOUT OUR METHODOLOGIES Therapeutic EXPERTISE Our specialised units in 4 locations handle indications that range from cardiovascular to respiratory. SEE OUR EXPERTISE BY INDICATION Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.ScienceEffect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.SciencePharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment.ScienceVildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.Science read more in our blog Studies in cooperation with: REACHING OUT IS EASY AND FAST – LET’S TALK Prof. Dr. Thomas Forst Chairman of the Executive Boardlocated at CRS Mannheim LET’S TALK SCIENCE *protected email*+49 621 150 45 – 0 Dr. Marc Hetzel VP & Head of Business Developmentlocated at CRS Management LET’S TALK BUSINESS *protected email*+49 621 150 45 – 0 CRO Leadership Awards 2019 CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability. European Biotechnology Guide Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019. EcoVadis – CSR Rating Based on the CSR rating by EcoVadis in 2022 CRS has been granted Silver Recognition Level.